Overview

Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the incidence of complete and partial response and the duration of response in patients with Langerhans Cell Histiocytosis (LCH) treated with sequential administration of oral 6-Thioguanine (6-TG) after Methotrexate (MTX).
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Calcium
Leucovorin
Levoleucovorin
Methotrexate
Thioguanine